News

Published on 6 May 2024 on Zacks via Yahoo Finance

Why Earnings Season Could Be Great for Nuvalent (NUVL)


Article preview image

Investors are always looking for stocks that are poised to beat at earnings season and Nuvalent, Inc. NUVL may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Nuvalent is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for NUVL in this report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 65 cents per share for NUVL, narrower than the broader Zacks Consensus Estimate of a loss of 67 cents per share. This suggests that analysts have very recently bumped up their estimates for NUVL, giving the stock a Zacks Earnings ESP of +2.50% heading into earnings season.

Nuvalent, Inc. Price and EPS Surprise

Nuvalent, Inc. price-eps-surprise | Nuvalent, Inc. Quote

NASDAQ.NUVL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. ...

Insider Monkey · via Yahoo Finance 22 Sep 2024

Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In t...

Insider Monkey · via Yahoo Finance 22 Sep 2024

Why Earnings Season Could Be Great for Nuvalent (NUVL)

Investors are always looking for stocks that are poised to beat at earnings season and Nuvalent, ...

Zacks via Yahoo Finance 6 May 2024

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)

Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted thera...

GuruFocus.com via Yahoo Finance 5 Apr 2024

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch

Few corners of the market have been as prone to dealmaking over the last couple of years as the l...

Investing.com 4 Apr 2024

Nuvalent director Matthew Shair sells over $2.8 million in company stock

Nuvalent, Inc. ( NASDAQ :NUVL) Director Matthew Shair has recently sold a significant amount of t...

Investing.com 2 Apr 2024

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)

Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted thera...

GuruFocus.com via Yahoo Finance 30 Mar 2024

Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)

Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted thera...

GuruFocus.com via Yahoo Finance 25 Mar 2024

Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)

Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted thera...

GuruFocus.com via Yahoo Finance 19 Mar 2024

Nuvalent advances cancer drug trials, maintains strong cash position By Investing.com

Nuvalent advances cancer drug trials, maintains strong cash position

Investing.com 27 Feb 2024